title: Editorial comment.
authors.affiliation: Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
authors.forename: Terhi
authors.initials: T
authors.lastname: Hermanson
authors.affiliation: Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane Medical School, New Orleans, LA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.affiliation: Department of Pathology, University of Arizona College of Medicine, Tucson, AZ.
authors.forename: Richard
authors.initials: R
authors.lastname: Ablin
authors.affiliation: College of Pharmacy, Medical University of South Carolina Cancer Center, Charleston, SC.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D050397:Radiotherapy, Intensity-Modulated
chemical_list: D000726:Androgen Antagonists